References
- Hutchinson L, Kirk R. High drug attrition rates–where are we going wrong? Nat Rev Clin Oncol 2011; 8:189-90; PMID:21448176; http://dx.doi.org/10.1038/nrclinonc.2011.34
- van der Worp HB, Howells DW, Sena ES, Porritt MJ, Rewell S, O'Collins V, Macleod MR. Can animal models of disease reliably inform human studies? PLoS Med 2010; 7:e1000245; PMID:20361020; http://dx.doi.org/10.1371/journal.pmed.1000245
- Bissell MJ, Hines WC. Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression. Nat Med 2011; 17:320-9; PMID:21383745; http://dx.doi.org/10.1038/nm.2328
- Correia AL, Bissell MJ. The tumor microenvironment is a dominant force in multidrug resistance. Drug Resist Updat 2012; 15:39-49; PMID:22335920; http://dx.doi.org/10.1016/j.drup.2012.01.006
- Goodbye, flat biology? Nature 2003; 424:861; PMID:12931146
- Kimlin LC, Casagrande G, Virador VM. In vitro three-dimensional (3D) models in cancer research: an update. Mol Carcinog 2013; 52:167-82; PMID:22162252; http://dx.doi.org/10.1002/mc.21844
- Grayson WL, Frohlich M, Yeager K, Bhumiratana S, Chan ME, Cannizzaro C, Wan LQ, Liu XS, Guo XE, Vunjak-Novakovic G. Engineering anatomically shaped human bone grafts. Proc Natl Acad Sci U S A 2010; 107:3299-304; PMID:19820164; http://dx.doi.org/10.1073/pnas.0905439106
- Marolt D, Campos IM, Bhumiratana S, Koren A, Petridis P, Zhang G, Spitalnik PF, Grayson WL, Vunjak-Novakovic G. Engineering bone tissue from human embryonic stem cells. Proc Natl Acad Sci U S A 2012; 109:8705-9; PMID:22586099; http://dx.doi.org/10.1073/pnas.1201830109
- de Peppo GM, Marcos-Campos I, Kahler DJ, Alsalman D, Shang L, Vunjak- Novakovic G, Marolt D. Engineering bone tissue substitutes from human induced pluripotent stem cells. Proc Natl Acad Sci U S A 2013; 110:8680-5; PMID:23653480; http://dx.doi.org/10.1073/pnas.1301190110
- Correia C, Grayson WL, Park M, Hutton D, Zhou B, Guo XE, Niklason L, Sousa RA, Reis RL, Vunjak-Novakovic G. In vitro model of vascularized bone: synergizing vascular development and osteogenesis. PLoS One 2011; 6:e28352; PMID:22164277; http://dx.doi.org/10.1371/journal.pone.0028352
- Villasante A, Marturano-Kruik A, Vunjak-Novakovic G. Bioengineered human tumor within a bone niche. Biomaterials 2014; 35:5785-94; PMID:24746967; http://dx.doi.org/10.1016/j.biomaterials.2014.03.081
- Smalley KS, Lioni M, Herlyn M. Life isn't flat: taking cancer biology to the next dimension. In Vitro Cell Dev Biol Anim 2006; 42:242-7; PMID:17163781; http://dx.doi.org/10.1290/0604027.1
- Chitcholtan K, Asselin E, Parent S, Sykes PH, Evans JJ. Differences in growth properties of endometrial cancer in three dimensional (3D) culture and 2D cell monolayer. Exp Cell Res 2013; 319:75-87; PMID:23022396; http://dx.doi.org/10.1016/j.yexcr.2012.09.012
- Rucci N, Teti A. Osteomimicry: how tumor cells try to deceive the bone. Front Biosci (Schol Ed) 2010; 2:907-15; PMID:20515833; http://dx.doi.org/10.2741/S110
- Barnes GL, Javed A, Waller SM, Kamal MH, Hebert KE, Hassan MQ, Bellahcene A, Van Wijnen AJ, Young MF, Lian JB, et al. Osteoblast-related transcription factors Runx2 (Cbfa1/AML3) and MSX2 mediate the expression of bone sialoprotein in human metastatic breast cancer cells. Cancer Res 2003; 63:2631-7; PMID:12750290
- Guelcher SA, Sterling JA. Contribution of bone tissue modulus to breast cancer metastasis to bone. Cancer Microenviron 2011; 4:247-59; PMID:21789687; http://dx.doi.org/10.1007/s12307-011-0078-3
- Olechnowicz SW, Edwards CM. Contributions of the host microenvironment to cancer-induced bone disease. Cancer Res 2014; 74:1625-31; PMID:24599133; http://dx.doi.org/10.1158/0008-5472.CAN-13-2645
- Mori G, D'Amelio P, Faccio R, Brunetti G. The Interplay between the bone and the immune system. Clin Dev Immunol 2013; 2013:720504; PMID:23935650; http://dx.doi.org/10.1155/2013/720504
- Spiller K. Bioengineering disease models: How to build a better bone tumor. Sci Transl Med 2014; 6:235.